Suvorexant is a prescription drug used to treat insomnia by blocking orexin receptors, which regulate wakefulness, thereby promoting sleep. Developed by Merck & Co., it was first approved by the U.S. FDA in 2014. Suvorexant represents a novel class of sleep aids dual orexin receptor antagonists (DORAs) and marked a shift from traditional sedative-hypnotics by targeting the brain’s wake-promoting system rather than enhancing GABAergic activity.
Image
